The role of cell cycle in the efficiency and activity of cancer nanomedicines

Expert Opinion on Drug Delivery

Volumn 10, Issue 6, 2013, Pages 775-786

  Abouzeid, Abraham H ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cell cycle; Combination therapy; Gene therapy; Nanoparticle uptake; Three dimensional cell cultures

Indexed keywords

CYTARABINE; CYTOTOXIC AGENT; NANOCARRIER; POLYETHYLENEIMINE; THYMIDINE KINASE; VORINOSTAT;

CANCER THERAPY; CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL HETEROGENEITY; CYTOSOL; DAUGHTER CELL; ENDOCYTOSIS; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HUMAN; IMMUNOGENICITY; MALIGNANT TRANSFORMATION; NANOMEDICINE; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; SPHEROID CELL;

ANIMALS; CELL CYCLE; CELL DIVISION; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84878030294     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.776538     Document Type: Review

References (73)

1. Bhattacharjee S, Ershov D, Fytianos K, et al. Cytotoxicity and cellular uptake of tri-block copolymer nanoparticles with different size and surface characteristics. Part Fibre Toxicol 2012;9:11
2. Sohaebuddin SK, Thevenot PT, Baker D, et al. Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol 2010;7:22
3. Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008;3(3):145-50
4. Massague J. G1 cell-cycle control and cancer. Nature 2004;432:298-306
5. Dethlefsen LA, Bauer KD, Riley RM. Analytical cytometric approaches to heterogeneous cell populations in solid tumors: a review. Cytometry 1980;1:89-97
6. Hartwell LH. Cell cycle control and cancer. Science 1994;266(5192):1821-8
7. Foster I. Cancer: a cell cycle defect. Radiography 2008;14(2):144-9
8. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988;240(4849):177+
9. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001;7(8):2168-81
10. Jedema I, Barge RMY, Frankel AE, et al. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colonystimulating factor/diphtheria toxin fusion proteins. Exp Hematol 2004;32(2):188-94
11. Jedema I, Barge RM, Willemze R, Falkenburg JH. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia 2003;17(3):576-84
12. Jedema I, Barge RM, van der Velden VH, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004;18(2):316-25
13. Jedema I, Barge RM, Nijmeijer BA, et al. Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia 2003;17(10):2049-51
14. Lowenberg B DJ, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62
15. Horber DH, von Ballmoos P, Schott H, Schwendener H. Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-b- Darabinofuranosylcytosine. Br J Cancer 1995;72(5):1067-73
16. Weichselbaum RR, Hellman S, Piro AJ, et al. Proliferation kinetics of a human breast cancer line in vitro following treatment with 17beta-estradiol and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1978;38(8):2339-42
17. Botenbal M, Sieuwerts AM, Peters HA, et al. Manipulation of cell cycle kinetics; influence on uptake, cellular distribution and cytotoxicity of doxorubicin. Eur J Cancer Clinl Oncol 1990;26(2):162
18. Zheng S, Chen J-Y, Wang J-Y, et al. Effects of cell cycle on the uptake of water soluble quantum dots by cells. J Appl Phys 2011;110(12):124701
19. Go EJ, Kim EJ, Hur W. In vitro cellular uptake of fibroin microspheres and its dependency on the cell cycle stage. J Microencapsul 2013;30(2):124-131
20. Roa W, Zhang X, Guo L, et al. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology 2009;20(37):375101
21. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996;12:575-625
22. Warren G, Davoust J, Cockcroft A. Recycling of transferrin receptors in A431 cells is inhibited during mitosis. EMBO 1984;3(10):2217-25
23. Fielding AB, Willox AK, Okeke E, et al. Clathrin-mediated endocytosis is inhibited during mitosis. Proc Nat Acad Sci USA 2012;109(17):6572-7
24. Raucher D, Sheetz MP. Membrane expansion increases endocytosis rate during mitosis. J Cell Biol 1999;14(3):497-506
25. Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nano 2012;7(1):62-8
26. Errington RJ, Brown MR, Silvestre OF, et al. Single cell nanoparticle tracking to model cell cycle dynamics and compartmental inheritance. Cell Cycle 2010;9(1):121-30
27. Symens N, Soenen SJ, Rejman J, et al. Intracellular partitioning of cell organelles and extraneous nanoparticles during mitosis. Adv Drug Deliv Rev 2012;64(1):78-94
28. Zabner J, Fasbender AJ, Moninger T, et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995;270(32):8997- 9007
29. Nicolau C, Sene C. Liposome-mediated DNA transfer in eukaryotic cells: dependence of the transfer efficiency upon the type of liposomes used and the host cell cycle stage. Biochim Biophys Acta BBAMol Cell Res 1982;721(2):185-90
30. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm 2001;229(1-2):1-21
31. Wong SY, Pelet JM, Putnam D. Polymer systems for gene delivery-Past, present, and future. Prog Polym Sci 2007;32(8-9):799-837
32. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 2010;40(3):159-70
33. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther 2010;17:439-47
34. Nie Y, Schaffert D, Rodl W, et al. Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. J Control Release 2011;152(1):127-34
35. Brunner S, Furtbauer E, Sauer T, et al. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol Ther 2002;5(1):80-6
36. Ko YT, Kale A, Hartner WC, et al. Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J Controll Release 2009;133(2):132-8
37. Brunner S, Sauer T, Carotta S, et al. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther 2000;7(5):401
38. Prasmickaite L, Høgset A, Berg K. The role of the cell cycle on the efficiency of photochemical gene transfection. Biochim Biophys Acta (BBA) 2002;1570:210-18
39. Yu JN, Ma SF, Miao DQ, et al. Effects of cell cycle status on the efficiency of liposome-mediated gene transfection in mouse fetal fibroblasts. J Reprod Dev 2006;52(3):373-82
40. Mannisto M, Reinisalo M, Ruponen M, et al. Polyplex-mediated gene transfer and cell cycle: effect of carrier on cellular uptake and intracellular kinetics, and significance of glycosaminoglycans. J Gene Med 2007;479-87
41. Mannisto M, Ronkko S, Matto M, et al. The role of cell cycle on polyplex-mediated gene transfer into a retinal pigment epithelial cell line. J Gene Med 2005;4:466-76
42. Helin V, Gottikh M, Mishal Z, et al. Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture. Biochem Pharmacol 1999;58(1):95-107
43. Capecchi MR. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980;22(2 Part 2):479-88
44. Liu G, Li D, Pasumarthy MK, et al. nanoparticles of compacted DNA transfect postmitotic cells. J Biol Chem 2003;278(35):32578-86
45. Mehta G, Hsiao AY, Ingram M, et al. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 2012;164(2):192-204
46. Mehta G, Hsiao AY, Ingram M, et al. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 2012;164(2):192-204
47. Breslin S, O'Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 2012:1-10
48. Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen 2006;11(8):922-32
49. Freyer JP, Sutherland RM. Selective dissociation and characterization of cells from different regions of multicell tumor spheroids. Cancer Res 1980;40(11):3956-65
50. Venkatasubramanian R, Henson MA, Forbes NS. Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. J Theoret Biol 2008;253(1):98-117
51. Wartenberg M, Fischer K, Hescheler J, Sauer H. Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. Biochim Biophys Acta BBAMol Cell Res 2002;1589(1):49-62
52. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6(8):583-92
53. Poland J, Sinha P, Siegert A. Comparison of protein expression profiles between monolayer and spheroid cell culture of HT-29 cells revealed fragmentation of CK18 in three-dimensional cell culture. Electrophoresis 2002;23(7-8):1174-84
54. Chang TT, Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng 2009;15(3):559-67
55. Sonoda T, Kobayashi H, Kaku T, et al. Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines. Cancer Lett 2003;196(2):229-37
56. Lobjois V, Frongia C, Jozan S, et al. Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. Eur J Cancer 2009;45(13):2402-11
57. Mitra M, Mohanty C, Harilal A, et al. A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol Vis 2012;18:1362-78
58. Chen HH, Chien CC, Petibois C, et al. Quantitative analysis of nanoparticle internalization in mammalian cells by high resolution X-ray microscopy. J Nanobiotechnol 2011;9:14
59. Powathil GG, Gordon KE, Hill LA, Chaplain MAJ. Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. J Theor Biol 2012;308(0):1-19
60. SB H. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5(6):S3-6
61. Dibb M, Ang YS. Targeting the cell cycle in esophageal adenocarcinoma: an adjunct to anticancer treatment. World J Gastroenterol 2011;17(16):2063-9
62. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8(7):547-66
63. Danhier F, Ucakar B, Magotteaux N, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm 2010;392(1-2):20-8
64. Narang AS, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 2007;345(1-2):9-25
65. Li P, Tabibi SE, Yalkowsky SH. Solubilization of ionized and un-ionized flavopiridol by ethanol and polysorbate. J Pharm Sci 1999;88(5):507-9
66. Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine 2009;5(2):178-83
67. Raymond E, ten Bokkel Huinink WW, Taieb J, et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 2002;20:3508
68. Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012;163(1):34-45
69. Yang X, Zhao X, Phelps MA, et al. A novel liposomal formulation of flavopiridol. Int J Pharm 2009;365(1-2):170-4
70. George S, Kasimis BS, Cogswell J, et al. et al. Study of Flavopiridol in Combination with Paclitaxel and Carboplatin in Patients with Non-Small-Cell Lung Cancer. Clin Lung Cancer 2008;9(3):160-5
71. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.pdf. Molecular cancer therapeutics 2004;3(11):1427-38
72. Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res 2008;68(14):5519-23
73. Desoize B. Contribution of three-dimensional culture to cancer research. Crit Rev Oncol Hematol 2000;36(2-3):59-60